AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Crinetics Pharmaceuticals... (CRNX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

36.86

0.26 (0.71%)

At close: Feb 20, 2025, 3:59 PM

36.86

0.00%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	36
Market Cap	3.42B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.7
PE Ratio (ttm)	-9.96
Forward PE	n/a
Analyst	Buy

Ask	37
Volume	467,524
Avg. Volume (20D)	841,466
Open	36.53
Previous Close	36.60
Day's Range	35.78 - 36.98
52-Week Range	34.07 - 62.53
Beta	undefined

About CRNX

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat c...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 18, 2018

Employees 290

Stock Exchange NASDAQ

Ticker Symbol CRNX

Website https://www.crinetics.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for CRNX stock is "Buy." The 12-month stock price forecast is $73, which is an increase of 98.05% from the latest price.

Buy 91.67%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Crinetics Pharmaceuticals Inc. is scheduled to release its earnings on Feb 27, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

+1.26%

Crinetics Pharmaceuticals shares are trading highe... Unlock content with Pro Subscription

6 months ago

-6.11%

Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, the company announced its CFO will be departing and Oppenheimer lowered its price target on the stock from $74 to $73.

News

1 month ago · seekingalpha.com

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Crinetics Pharmaceuticals is currently overvalued but holds strong Wall Street support with a $75.07 average price target, indicating a 47.43% upside. The FDA accepted Crinetics' NDA for paltusotine, ...